Corpus overview


Overview

MeSH Disease

Infections (499)

Disease (455)

Coronavirus Infections (263)

Pneumonia (174)

Death (171)


Human Phenotype

Pneumonia (196)

Fever (60)

Cough (32)

Hypertension (21)

Falls (20)


Transmission

Seroprevalence
    displaying 691 - 700 records in total 1389
    records per page




    Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients

    Authors: Leonidas Palaiodimos; Natalia Chamorro-Pareja; Dimitrios Karamanis; Weijia Li; Phaedon D Zavras; Priyanka Mathias; Damianos G Kokkinidis

    doi:10.1101/2020.05.26.20113811 Date: 2020-05-28 Source: medRxiv

    Background: Infectious diseases MESHD are more frequent and can be associated with worse outcomes in patients with diabetes. Our aim was to systematically review and synthesize with a meta-analysis the available observational studies reporting the effect of diabetes in mortality among hospitalized patients with COVID-19. Methods: Medline, Embase, Google Scholar, and medRxiv databases were reviewed. A random-effect model meta-analysis was used and I-square was utilized to assess the heterogeneity. In-hospital mortality was defined as the endpoint. Sensitivity SERO, subgroup, and meta-regression analyses were performed. Results: 18,506 patients were included in this meta-analysis (3,713 diabetics and 14,793 non-diabetics). Patients with diabetes were associated with a higher risk of death MESHD compared to patients without diabetes (OR: 1.65; 95% CI: 1.35, 1.96; I2 77.4%). The heterogeneity was high. A study level meta-regression analysis was performed for all the important covariates and no significant interactions were found between the covariates and the outcome of mortality. Conclusion: This meta-analysis shows that that the likelihood of death MESHD is 65% higher in diabetic hospitalized patients with COVID-19 compared to non-diabetics. Further studies are needed to assess whether this association is independent or not, as well as to investigate to role of glucose control prior or during the disease MESHD.

    Classification Of X-ray Images For Detecting Covid-19 Using Deep Transfer Learning 

    Authors: Nidhi Bansal; S.Sridhar

    doi:10.21203/rs.3.rs-32247/v1 Date: 2020-05-28 Source: ResearchSquare

    The coronavirus disease MESHD COVID-19 eruption is stated as a pandemic by the World Health Organization. It is affecting around 212 countries and territories across the globe. There is a need to constantly analyze and find patterns from lungs X-Ray images. Early diagnosis can constraint the exposure of person and aids to bound the feast of the virus. The manual diagnosis is quite tedious and time-consuming process. The main aim of this paper is to explore the transfer learning potential. A deep learning framework is proposed adopting the capability of pretrained Deep Convolutional Neural Network models with transfer learning. This assists in classification of the chest X-Ray Images with high level of accuracy. An analysis is done with utilization of six pretrained models – VGG16, VGG19, ResNet50V2, InceptionV3, Xception and NASNetLarge. The experiment results showed that the highest accuracy obtained was 97% using VGG16 and VGG19 with sensitivity SERO and specificity of 100% and 94% respectively.  

    Early prediction for severe COVID-19 with hypertension and intervention

    Authors: Denggao Peng; Yanzhang Gao; Zhenyu Zhou; Huan Wang; Anjue Tang

    doi:10.21203/rs.3.rs-31888/v1 Date: 2020-05-28 Source: ResearchSquare

    Background To identify the early predictors of severe coronavirus disease MESHD 2019 (COVID-19) with hypertension MESHD hypertension HP,explore antihypertensive drugs with potential therapeutic effects, and provide a basis for clinical prediction and treatment decisions.Method: A retrospective study was performed on all included cases.Results A total of 68 COVID-19 patients with hypertension MESHD hypertension HP were included,27 (39.7%) was severe and 41 (60.3%) was non-severe. Between the non-severe group (n = 41) and the severe group (n = 27),number of elevated B-type natriuretic peptide (BNP) and abnormal renal function,and albumin,lactate dehydrogenase,ultrasensitive troponin I,PH Value,arterial carbon dioxide partial pressure,sodium,osmotic pressure (OP), blood SERO sugar (BS) and oxygenation index (OI) are significantly different.While age TRANS, male TRANS gender TRANS,comorbidities with diabetes or atherosclerotic cardiovascular disease MESHD,smoking history,number of abnormal liver function,heart rate,respiratory rate, blood SERO pressure,white blood SERO cell count,hematocrit,potassium and lactic acid are statistically insignificant.Four independent predictors of BNP (P = .026),OP (P = .004),BS (P = .017) and OI (P = .001) are obtained through multivariate binary logistic regression model.The area under curve (AUC) of receiver operating characteristic (ROC) of model is 0.904 ([95%CI] [0.832–0.976];P = .000),with excellent performance SERO.Compared with blank control group (n = 27) and other antihypertensive drugs group (n = 20),OP ([287.3 ± 5.7] vs [283.5 ± 6.1];P = .045) ([287.3 ± 5.7] vs [281.9 ± 5.4];P = .007) in renin-angiotensin-aldosterone system (RAS) inhibitors group (n = 21) have increased significantly.Compared with controlled blood SERO pressure group (n = 30),OP ([285.7 ± 6.2] vs [282.2 ± 5.2];P = .012) of uncontrolled group (n = 38) increased significantly.Conclusion Decreased OP and OI, increased BNP and BS are early predictors for severe COVID-19 patients with hypertension MESHD hypertension HP.For poorly controlled blood SERO pressure,targeting RAS and OP,early use of RAS inhibitors or combination with loop diuretics may be an effective treatment.

    Elevated serum SERO ferritin level effectively discriminates severity illness and predicts prognosis of COVID-19 patients

    Authors: Peng Cao; Yuanjue Wu; Sanlan Wu; Tingting Wu; Qilin Zhang; Rui Zhang; Yongning Lu; Yu Zhang

    doi:10.21203/rs.3.rs-31914/v1 Date: 2020-05-28 Source: ResearchSquare

    During coronavirus disease MESHD 2019 (COVID-19) pandemic, medical resources in every country is in shortage. Efficacious indicators of discriminating severe illness and predicting outcome is in urgent need. We collected data and clinical records from 79 COVID-19 patients admitted between January 12, 2020 and February 21, 2020 at Wuhan Union hospital, China. Spearman’s correlation analysis, receiver operating characteristic (ROC) curve, logistic regression model, and Kaplan-Meier survival curves were employed in the analysis. Of 79 patients enrolled, 2 died in hospital, 8 were transferred to other hospitals, and 69 were discharged. Patients with elevated ferritin levels (> 200 ng/mL) had a higher incidence of severity illness when compared with those with normal ferritin levels (≤ 200 ng/mL) (50.0% vs 2.9%). In addition, severity illness manifested significantly higher level of ferritin as compared with non-severe ones (median 921.3 vs 130.7 ng/mL, p < 0.001). Furthermore, ferritin could effectively discriminate severity and non-severity, with an area under the ROC curve (AUC) reaching 0.873 ( sensitivity SERO 96%, specificity 70%), larger than that of age TRANS (0.697), C-reactive protein (0.730) and lymphocytes% (0.717). Combined model incorporating multivariate revealed a similar manner with ferritin alone (p = 0.981). Furthermore, elevated ferritin group showed longer viral clearance time (median 16 vs 6 days, p < 0.001) and in-hospital length (median 18 vs 10 days, p < 0.001). Our results suggest that ferritin could act as a simple and efficacious complementary tool to identify severe COVID-19 patients at early stage and predict their outcome. This indicator would provide guidance for subsequent clinical practice, alleviate the medical stress and reduce the mortality.

    Early fibroproliferative changes on high-resolution CT predict mortality in COVID-19 pneumonia MESHD pneumonia HP patients with ARDS

    Authors: Zhilin Zeng; Min Xiang; Hanxiong Guan; Yiwen liu; huilan Zhang; Liming Xia; Zhan Juan; Qiongjie Hu

    doi:10.21203/rs.3.rs-32245/v1 Date: 2020-05-28 Source: ResearchSquare

    Objectives: To investigate the chest high-resolution CT (HRCT) findings in coronavirus disease MESHD 2019 (COVID-19) pneumonia MESHD pneumonia HP patients with acute respiratory distress HP syndrome MESHD (ARDS) and to evaluate its relationship with clinical outcome.Materials and Methods In this retrospective study, seventy-nine COVID-19 patients with ARDS were recruited. Clinical data were extracted from electronic medical records and analyzed. HRCT scans, obtained within 3 days before clinical ARDS onset, were evaluated by three independent observers and graded into six findings according to the extent of fibroproliferation. Multivariable Cox proportional hazard regression analysis was used to assess the independent predictive value of the CT score and radiologically fibroproliferation. Patient survival was determined by Kaplan-Meier analysis.Results: Compared with survivors, non-survivors showed higher of lung fibroproliferation, whereas there no significant differences in the area of increased attenuation without traction bronchiolectasis HP or bronchiectasis MESHD bronchiectasis HP. A HRCT score <230 enabled prediction of survival with 73.5% sensitivity SERO and 93.3% specificity (AUC= 0.9; 95% CI 0.831 to 0.968). Multivariate Cox proportional hazards model showed that the HRCT score is a significant independent risk factor for mortality (HR 13.007; 95% CI 3.935 to 43.001). Kaplan-Meier analysis revealed HRCT score≥230 was associated with higher fatality rate. Organ injury occurred less frequently in patients with HRCT score<230 compared to those with HRCT score≥230.Conclusion: Early pulmonary fibroproliferative changes in HRCT predicts increased mortality and susceptibility to organ injury in COVID-19 pneumonia MESHD pneumonia HP patients with early ARDS.

    Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2

    Authors: Jon Arizti-Sanz; Catherine A. Freije; Alexandra C. Stanton; Chloe K. Boehm; Brittany A. Petros; Sameed Siddiqui; Bennett M. Shaw; Gordon Adams; Tinna-Solveig F. Kosoko-Thoroddsen; Molly E. Kemball; Robin Gross; Loni Wronka; Katie Caviness; Lisa E. Hensley; Nicholas H. Bergman; Bronwyn L. MacInnis; Jacob E. Lemieux; Pardis C. Sabeti; Cameron Myhrvold

    doi:10.1101/2020.05.28.119131 Date: 2020-05-28 Source: bioRxiv

    The COVID-19 pandemic has highlighted that new diagnostic technologies are essential for controlling disease MESHD transmission TRANS. Here, we develop SHINE (SHERLOCK and HUDSON Integration to Navigate Epidemics), a sensitive and specific integrated diagnostic tool that can detect SARS-CoV-2 RNA from unextracted samples. We combine the steps of SHERLOCK into a single-step reaction and optimize HUDSON to accelerate viral inactivation in nasopharyngeal swabs and saliva. SHINEs results can be visualized with an in-tube fluorescent readout -- reducing contamination risk as amplification reaction tubes remain sealed -- and interpreted by a companion smartphone application. We validate SHINE on 50 nasopharyngeal patient samples, demonstrating 90% sensitivity SERO and 100% specificity compared to RT-PCR with a sample-to-answer time of 50 minutes. SHINE has the potential to be used outside of hospitals and clinical laboratories, greatly enhancing diagnostic capabilities.

    Evaluation of commercial qPCR kits for detection of SARS-CoV-2 in pooled samples

    Authors: Vlad Petrovan; Virgil Vrajmasu; Paula Dimon; Mihaela Zaulet

    doi:10.1101/2020.05.28.120667 Date: 2020-05-28 Source: bioRxiv

    Due to the current pandemic, global shortage of reagents has drawn interest in developing alternatives to increase the number coronavirus tests. One such alternative is sample pooling. Here we compared commercial kits that are used in COVID-19 diagnostics, in terms of sensitivity SERO and feasibility for use in pooling. We showed that pooling of up to 60 samples did not affect the efficiency of the kits. Also, the RNA dependent RNA polymerase (RdRp) is a more suitable target in pooled samples than the Envelope (E) protein. This approach could provide an easy method of screening large number of samples and help adjust different government regulations.

    Evaluation of performance SERO of two SARS-CoV-2 Rapid whole- blood SERO finger-stick IgM-IgGCombined Antibody Tests SERO

    Authors: Thierry Prazuck; Mathilda Colin; Susanna Giache; Camelia Gubavu; Aymeric Seve; Vincent Rzepecki; Marie Chevereau-Choquet; Catherine Kiani; Victor Rodi; Elsa Lyonnet; Laura Courtellemont; Jerome Guinard; Gilles Pialoux; Laurent Hocqueloux

    doi:10.1101/2020.05.27.20112888 Date: 2020-05-27 Source: medRxiv

    Background The SARS-CoV-2 virus is responsible for the infectious respiratory disease MESHD called COVID-19 ( COronaVIrus Disease MESHD). In response to the growing COVID-19 pandemic, Rapid Diagnostic Tests (RDTs) have been developed to detect specific antibodies, IgG and IgM SERO, to SARS-CoV-2 virus in human whole blood SERO. We conducted a real-life study to evaluate the performance SERO of two RDTs, COVID-PRESTO and COVID-DUO, compared to the gold standard, RT-PCR. Methods RT-PCR testing of SARS-Cov-2 was performed from nasopharyngeal swab specimens collected in adult TRANS patients visiting the infectious disease MESHD department at the hospital (Orleans, France). Fingertip whole blood SERO samples taken at different time points after onset of the disease MESHD were tested with RDTs. The specificity and sensitivity SERO of the rapid test SERO kits compared to test of reference (RT-PCR) were calculated. Results Among 381 patients with symptoms of COVID-19 who went to the hospital for a diagnostic, 143 patients were RT-PCR negative. Results of test with RDTs were all negative for these patients, indicating a specificity of 100% for both RDTs. In the RT-PCR positive subgroup (n=238), 133 patients were tested with COVID-PRESTO and 129 patients were tested with COVID-DUO (24 patients tested with both). The further the onset of symptoms TRANS was from the date of collection, the greater the sensitivity SERO. The sensitivity SERO of COVID-PRESTO test ranged from 10.00% for patients having experienced their 1st symptoms from 0 to 5 days ago to 100% in patients where symptoms had occurred more than 15 days before the date of tests. For COVID-DUO test, the sensitivity SERO ranged from 35.71% [0-5 days] to 100% (> 15 days). Conclusion COVID-PRESTO and DUO RDTs turned out to be very specific (none false positive) and to be sensitive enough after 15 days from onset of symptom TRANS. These easy to use IgG/IgM combined test kits are the first ones allowing a screening with capillary blood SERO sample, by typing from a finger prick. These rapid tests SERO are particularly interesting for screening in low resource settings.

    Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis

    Authors: Laszlo Mark Czumbel; Szabolcs Kiss; Nelli Farkas; Ivan Mandel; Anita Emoke Hegyi; Akos Karoly Nagy; Zsolt Lohinai; Zsolt Szakacs; Peter Hegyi; Martin C. Steward; Gabor Varga

    doi:10.1101/2020.05.26.20112565 Date: 2020-05-27 Source: medRxiv

    Objectives: Our aim was to conduct a meta-analysis on the reliability and consistency of SARS-CoV-2 viral RNA detection in saliva specimens. Methods: We reported our meta-analysis according to the Cochrane Handbook. We searched the Cochrane Library, Embase, Pubmed, Scopus, Web of Science and clinical trial registries for eligible studies published between 1 January and 25 April 2020. The number of positive tests and total number of conducted tests were collected as raw data. The proportion of positive tests in the pooled data were calculated by score confidence interval estimation with the Freeman-Tukey transformation. Heterogeneity was assessed using the I2 measure and the Chi2 test. Results: The systematic search revealed 96 records after removal of duplicates. 26 records were included for qualitative analysis and 5 records for quantitative synthesis. We found 91% (95%CI = 80%-99%) sensitivity SERO for saliva tests and 98% (95%CI 89%-100%) sensitivity SERO for nasopharyngeal swab (NPS) tests in previously confirmed COVID-19 infected patients, with moderate heterogeneity among studies. Additionally, we identified 18 registered, ongoing clinical trials on saliva-based tests for detection of the virus. Conclusion: Saliva tests offer a promising alternative to NPS for COVID-19 diagnosis. However, further diagnostic accuracy studies are needed to improve their specificity and sensitivity SERO.

    THE LOW-HARM SCORE FOR PREDICTING MORTALITY IN PATIENTS DIAGNOSED WITH COVID-19: A MULTICENTRIC VALIDATION STUDY

    Authors: Adrian Soto-Mota; Braulio A. Marfil Garza; Erick Martinez Rodriguez; Jose Omar Barreto Rodriguez; Alicia Estela Lopez Romo; Paolo Alberti Minutti; Juan Vicente Alejandre Loya; Felix Emmanuel Perez Talavera; Freddy Jose Avila-Cervera; Adriana Nohemi Velazquez Burciaga; Oscar Morado Aramburo; Luis Alberto Pina Olguin; Adrian Soto-Rodriguez; Andres Castaneda Prado; Patricio Santillan-Doherty; Juan O Galindo Galindo; Daniel Hernandez Gordillo; Juan Gutierrez Mejia

    doi:10.1101/2020.05.26.20111120 Date: 2020-05-27 Source: medRxiv

    ABSTRACT - Importance: Many COVID-19 prognostic factors for disease MESHD severity have been identified and many scores have already been proposed to predict death MESHD and other outcomes. However, hospitals in developing countries often cannot measure some of the variables that have been reported as useful. - Objective: To assess the sensitivity SERO, specificity, and predictive values of the novel LOW-HARM score ( Lymphopenia MESHD Lymphopenia HP, Oxygen saturation, White blood SERO cells, Hypertension MESHD Hypertension HP, Age TRANS, Renal injury, and Myocardial injury). - Design: Demographic and clinical data from patients with known clinical outcomes ( death MESHD or discharge) was obtained. Patients were grouped according to their outcome. The LOW-HARM score was calculated for each patient and its distribution, potential cut-off values and demographic data were compared. - Setting: Thirteen hospitals in ten different cities in Mexico. - Participants: Data from 438 patients was collected. A total of 400 (200 per group) was included in the analysis. - Exposure: All patients had an infection MESHD with SARS-CoV-2 confirmed by PCR. - Main Outcome: The sensitivity SERO, specificity, and predictive values of different cut-offs of the LOW-HARM score to predict death MESHD. - Results: Mean scores at admission and their distributions were significantly lower in patients who were discharged compared to those who died during their hospitalization 10 (SD: 17) vs 71 (SD: 27). The overall AUC of the model was 95%. A cut-off > 65 points had a specificity of 98% and a positive predictive value SERO of 96%. More than a third of the cases (34%) in the sample had a LOW-HARM score > 65 points. - Conclusions and relevance: The LOW-HARM score measured at admission is highly specific and useful for predicting mortality. It is easy to calculate and can be updated with individual clinical progression. The proposed cut-off can assist the decision-making process in more than a third of the hospital admissions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.